Anti-Obesity Drugs Market to Reach US$ 43.7 Billion by 2030 at 45.5% CAGR; North America Leads with 45% Share - Key Players: Novo Nordisk, Eli Lilly, Pfizer

The Anti-Obesity Drugs Market was valued at US$ 2.5 billion in 2022 and is projected to reach US$ 43.7 billion by 2030, registering a CAGR of 45.5 percent during the forecast period 2024 to 2031. Obesity is a chronic condition marked by excess body fat that can negatively impact overall health, commonly defined by a body mass index of 30 or higher. It has become one of the fastest-growing public health challenges worldwide. Anti-obesity drugs are prescribed to assist individuals in weight management by reducing appetite, increasing metabolic activity, or limiting fat absorption.

Market expansion is fueled by the rising global prevalence of obesity, increasing health awareness, and a steady introduction of new products. Research efforts to develop more effective therapies, along with strategic initiatives such as collaborations, acquisitions, expansions, and mergers among industry participants, are further strengthening growth prospects. The growing focus on long-term weight management solutions continues to drive the demand for advanced anti-obesity treatments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/anti-obesity-drugs-market?sai-v

The Anti-Obesity Drugs Market refers to the industry developing medications designed to support weight loss by reducing appetite, controlling cravings, or improving metabolic processes in individuals with obesity.

Key Developments
✅ October 2025: Leading U.S. pharmaceutical companies expanded clinical programs evaluating next-generation GLP-1/GIP combination therapies to deliver superior weight-loss efficacy with improved metabolic outcomes.

✅ September 2025: European healthcare providers integrated AI-driven obesity management platforms with prescription obesity medications to personalize dosing, monitor adherence, and optimize long-term weight control.

✅ August 2025: Asia-Pacific drug manufacturers advanced oral GLP-1 formulations aimed at reducing injection dependency and improving patient convenience across emerging obesity treatment markets.

❇️ July 2025: Research institutions worldwide initiated multi-phase trials exploring dual-target and triple-agonist therapies focused on enhancing fat oxidation, appetite regulation, and cardiometabolic benefits.

✅ May 2025: Major pharmaceutical companies launched real-world studies assessing cardiovascular risk reduction benefits associated with chronic anti-obesity drug use.

✅ March 2025: Global clinical centers expanded adoption of digital weight-management ecosystems combining prescription drugs, behavioral therapy, and continuous metabolic monitoring.

Mergers & Acquisitions
❇️ November 2025: A U.S. metabolic-health pharmaceutical leader acquired a biotech developing novel incretin-based obesity drug candidates to strengthen its obesity pipeline.

✅ August 2025: A European pharmaceutical company formed a strategic partnership with an Asian digital health platform to integrate medication-assisted obesity programs with continuous lifestyle monitoring.

✅ June 2025: A North American drug developer acquired a clinical-stage obesity therapeutics startup specializing in peptide-based appetite suppressant molecules to expand its anti-obesity portfolio.

Key Players
Eli Lilly and Company | Bayer AG | Bristol-Myers Squibb | Currax Pharmaceuticals LLC | F. Hoffmann-La Roche AG | GlaxoSmithKline PLC | Merck & Co., Inc. | Norgine BV | Novo Nordisk AS | Pfizer Inc.

Key Highlights

Eli Lilly and Company - Holds an estimated 18.6% share, driven by its rapidly expanding GLP-1 portfolio, strong clinical outcomes, and next-generation obesity therapies such as tirzepatide that continue to gain global adoption.

Bayer AG - Accounts for approximately 7.4% share, supported by its diversified metabolic disorder portfolio, established international presence, and ongoing R&D investments targeting obesity-linked pathways.

Bristol-Myers Squibb - Represents around 6.1% share, fueled by its strategic initiatives in metabolic and cardiovascular health, and growing interest in therapies addressing obesity-related comorbidities.

Currax Pharmaceuticals LLC - Maintains roughly 4.9% share, driven by sustained demand for its chronic weight-management drug offerings and its strong positioning in prescription anti-obesity therapeutics.

F. Hoffmann-La Roche AG - Holds an estimated 5.7% share, backed by its longstanding presence in metabolic and endocrine disorders and continuous innovation in life-science research supporting obesity treatment.

GlaxoSmithKline PLC - Accounts for about 8.2% share, supported by its widely recognized OTC obesity treatment, strong consumer health distribution channels, and reliable global supply network.

Merck & Co., Inc. - Represents nearly 6.6% share, leveraging its advanced metabolic research programs, large R&D infrastructure, and growing efforts toward next-generation obesity-modulating treatments.

Norgine BV - Maintains approximately 3.5% share, attributed to its focused portfolio in gastrointestinal and metabolic health, supporting complementary treatment options for obesity-related conditions.

Novo Nordisk AS - Dominates the market with an estimated 24.3% share, driven by its blockbuster GLP-1 therapies (e.g., semaglutide), strong clinical efficacy data, global patient adoption, and a robust late-stage obesity pipeline.

Pfizer Inc. - Holds around 14.7% share, supported by its expanding metabolic and obesity drug pipeline, strategic focus on oral therapeutic innovation, and ongoing development of competitive GLP-1 alternatives.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market?sai-v

Market Drivers

- Rising global obesity prevalence due to sedentary lifestyles, unhealthy diets, and genetic predisposition.

- Growing awareness about obesity-related comorbidities such as diabetes, cardiovascular diseases, and hypertension.

- Increasing demand for effective weight management therapies beyond traditional diet and exercise.

- Advancements in pharmacotherapy, including GLP-1 agonists and combination therapies showing superior outcomes.

- Expanding healthcare expenditure and improved access to prescription weight-loss medications.

- Strong support from government health programs and public health campaigns promoting obesity treatment.

- Growing adoption of digital health platforms and telemedicine for obesity management and prescription follow-ups.

Industry Developments

- Launch of next-generation GLP-1 and dual/triple agonist drugs offering significant weight-loss efficacy.

- Strategic collaborations between pharmaceutical companies to co-develop advanced metabolic therapies.

- Expansion of clinical trials for novel anti-obesity mechanisms, including appetite regulation and fat metabolism pathways.

- Increasing FDA and EMA approvals for innovative weight-loss medications.

- Rising investment in personalized obesity treatment leveraging genomics and metabolic profiling.

- Development of long-acting injectable formulations and oral GLP-1 alternatives to improve patient compliance.

Regional Insights

North America - 45% share: "Driven by high obesity rates, strong presence of leading drug manufacturers, and rapid adoption of GLP-1 therapies."

Europe - 30% share: "Supported by rising healthcare awareness, government-led obesity prevention programs, and increasing drug approvals."

Asia Pacific - 18% share: "Fueled by growing obesity prevalence in urban populations and expanding access to advanced metabolic therapies."

Latin America - 4% share: "Boosted by rising lifestyle-related obesity cases and increasing uptake of prescription weight-loss drugs."

Middle East & Africa - 3% share: "Driven by growing obesity burden, expanding healthcare infrastructure, and rising demand for modern treatment options."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-obesity-drugs-market?sai-v

Key Segments

➥ By Vehicle
• Passenger Cars: Equipped with advanced autonomous features to enhance safety, driver convenience, and assisted driving capabilities for everyday mobility.
• Commercial Vehicles: Includes trucks, vans, and fleet vehicles adopting autonomous technologies to improve logistics efficiency, reduce operational costs, and enhance safety.

➥ By Level of Automation
• L1: Basic driver assistance features such as lane-keeping and adaptive cruise control with the driver remaining fully engaged.
• L2: Partial automation where the vehicle can control steering and speed simultaneously, but human supervision is still required.
• L3: Conditional automation enabling the vehicle to manage driving tasks in specific conditions while allowing the driver to intervene when prompted.
• L4: High automation capable of self-driving in most environments without human intervention, typically within predefined geofenced areas.
• L5: Full automation enabling completely driverless operation in all environments, conditions, and scenarios.

➥ By Application
• Robo-Taxis: Driverless ride-hailing vehicles designed to provide autonomous urban mobility and reduce reliance on traditional taxis.
• Logistics and Delivery: Autonomous vehicles used for parcel delivery, last-mile logistics, and freight transport, increasing speed and reducing human labor dependency.
• Personal Mobility: Self-driving vehicles used for individual travel, offering enhanced safety and convenience in daily commuting.
• Public Transportation: Autonomous shuttles and buses designed to improve mass transit efficiency, safety, and accessibility.
• Others: Includes autonomous industrial vehicles, shuttle pods, campus mobility systems, and specialized unmanned transport solutions.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.